LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

Search

Fulgent Genetics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

21.26 -2.25

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

21.14

Max

21.31

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-7.4M

-19M

Pardavimai

8.3M

82M

Pelno marža

-23.539

Darbuotojai

1,313

EBITDA

-3.5M

-15M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+14.68% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-07

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

82M

631M

Ankstesnė atidarymo kaina

23.51

Ankstesnė uždarymo kaina

21.26

Naujienos nuotaikos

By Acuity

50%

50%

157 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

Fulgent Genetics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-08-15 16:11; UTC

Pagrindinės rinkos jėgos

Health Insurers Climb as Berkshire Hathaway Takes UnitedHealth Stake

2025-08-15 22:22; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-08-15 22:22; UTC

Rinkos pokalbiai

Target Is Falling Behind Its Peers -- Market Talk

2025-08-15 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-08-15 20:33; UTC

Rinkos pokalbiai

U.S. Treasury Yields Close the Week Little Changed -- Market Talk

2025-08-15 20:25; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

This Meatpacker Stock Is a Quality Buy at a Discount Price -- Barrons.com

2025-08-15 20:24; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Nucor Stock Gets a Boost From Buffett. Berkshire's Last Steel Buy Didn't Go So Well. -- Barrons.com

2025-08-15 20:18; UTC

Uždarbis

Deere's Earnings Brought a Surprise. It Wasn't the Usual Kind. -- Barrons.com

2025-08-15 19:14; UTC

Rinkos pokalbiai

U.S. Natural Gas Settles Higher, But Down on Week -- Market Talk

2025-08-15 19:12; UTC

Rinkos pokalbiai

Oil Futures Settle Lower Ahead of U.S.-Russia Summit -- Market Talk

2025-08-15 18:32; UTC

Rinkos pokalbiai

Coffee Futures Surge on New Brazilian Frost -- Market Talk

2025-08-15 17:33; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Increases By 1 to 412 -- Market Talk

2025-08-15 17:23; UTC

Rinkos pokalbiai
Uždarbis

Deere's Earnings Appear to Be Troughing -- Market Talk

2025-08-15 16:27; UTC

Uždarbis

Tariffs Have Rocked e.l.f. Beauty Shares. Why the Fundamentals Still Look Alluring. -- Barrons.com

2025-08-15 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-08-15 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-08-15 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-08-15 16:05; UTC

Įsigijimai, susijungimai, perėmimai

Intel's Move Toward Nationalization Won't Work -- at Least for the Long Haul -- Heard on the Street -- WSJ

2025-08-15 15:52; UTC

Įsigijimai, susijungimai, perėmimai

What Applied Materials' Poor Outlook Means for Chip Stocks -- Barrons.com

2025-08-15 15:36; UTC

Rinkos pokalbiai

Base Metal Prices Mixed; Copper Gains as Focus Shifts to Fundamentals -- Market Talk

2025-08-15 15:29; UTC

Uždarbis

Deere's Earnings Brought a Surprise. It Wasn't the Usual Kind. -- Barrons.com

2025-08-15 15:29; UTC

Įsigijimai, susijungimai, perėmimai

Nucor Stock Gets a Boost From Buffett. Berkshire's Last Steel Buy Didn't Go So Well. -- Barrons.com

2025-08-15 15:28; UTC

Uždarbis

JD.com Stock Rises After Earnings Beat. Why Investors Are Relieved. -- Barrons.com

2025-08-15 15:24; UTC

Rinkos pokalbiai

Gold Futures Tick Higher But Remain Broadly Rangebound -- Market Talk

2025-08-15 15:08; UTC

Rinkos pokalbiai

Applied Materials Is Losing Share in Chips Business -- Market Talk

2025-08-15 14:38; UTC

Įsigijimai, susijungimai, perėmimai

African Rainbow Minerals to Own 19.9% of Surge Copper Shares

2025-08-15 14:37; UTC

Įsigijimai, susijungimai, perėmimai

African Rainbow Minerals to Buy 25.8 Million Surge Copper Shares for C$4.51M

2025-08-15 14:37; UTC

Įsigijimai, susijungimai, perėmimai

African Rainbow Minerals to Buy 25.8 Million Surge Copper Shares at C$0.175 Each

2025-08-15 14:36; UTC

Įsigijimai, susijungimai, perėmimai

African Rainbow Minerals to Acquire Shares of Surge Copper Corp.

2025-08-15 14:33; UTC

Įsigijimai, susijungimai, perėmimai

A Trump Intel Stake Could Make National Security the New 'Too Big to Fail' -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Fulgent Genetics Inc Prognozė

Kainos tikslas

By TipRanks

14.68% į viršų

12 mėnesių prognozė

Vidutinis 24.38 USD  14.68%

Aukščiausias 30 USD

Žemiausias 21 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Fulgent Genetics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

4 ratings

2

Pirkti

2

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

17.32 / 19.04Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bearish Evidence

Vidutinės trukmės periodas

Strong Bullish Evidence

Ilgalaikis periodas

Neutral Evidence

Rinkos nuotaikos

By Acuity

157 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Fulgent Genetics Inc

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.